The apolipoprotein E ϵ4 allele is not associated with psychiatric symptoms or extrapyramidal signs in probable Alzheimer's disease
Citation Manager Formats
Make Comment
See Comments
![Loading Loading](https://n.neurology.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
The objective of our study was to examine the relationship between the presence of the apolipoprotein E (apo E) ϵ4 allele, psychiatric symptoms, and extrapyramidal signs (EPS) in probable Alzheimer's disease(AD). The apo E ϵ4 allele modifies the risk and age at onset of AD. However, it still needs to be determined whether it is a marker for specific clinical subgroups. The frequency of clinical signs and symptoms was examined in 194 AD patients with the apo E ϵ3/3 (N = 79), ϵ3/4 (N = 96), andϵ4/4 (N = 19) genotypes participating in a longitudinal study of dementia. Each patient was assessed with semistructured psychiatric and neurologic examinations. Patients with the ϵ4/4 genotype had an earlier age at onset of dementia (p = 0.03). However, no individual psychiatric symptom or neurologic sign was associated with the presence of the apo E ϵ4 allele, including major depression (odds ratio [OR], 1.14; CI, 0.50 to 2.45; p = 0.78), psychosis (e.g., delusions and hallucinations) (OR, 0.66, CI, 0.35 to 1.25; p= 0.20), and EPS (in neuroleptic-free patients) (OR, 0.82, CI, 0.45 to 1.49; p = 0.52), after controlling by age at onset, duration of the symptoms, education, and severity of dementia. The presence of the apo E ϵ4 allele has limited utility in the characterization of neurologic and psychiatric subgroups in probable AD patients. The apo E ϵ4/4 genotype appears to be related to age at onset of AD, consistent with previous findings.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Dennis Bourdette and Dr. Lindsey Wooliscroft
► Watch
Related Articles
- No related articles found.
Alert Me
Recommended articles
-
Articles
Severity of cognitive impairment and the clinical diagnosis of AD with Lewy bodiesO.L. Lopez, R.L. Hamilton, J.T. Becker et al.Neurology, May 09, 2000 -
Articles
The relationship between extrapyramidal signs and cognitive performance in patients with Alzheimer's disease enrolled in the CERAD studyC. M. Clark, D. Ewbank, A. Lerner et al.Neurology, July 01, 1997 -
Articles
The pathology of the substantia nigra in Alzheimer disease with extrapyramidal signsJ. M. Burns, J. E. Galvin, C. M. Roe et al.Neurology, April 25, 2005 -
Articles
Effects of apolipoprotein E on dementia and aging in the Shanghai Survey of DementiaR. Katzman, M.-Y. Zhang, P. J. Chen et al.Neurology, September 01, 1997